[
  {
    "ts": null,
    "headline": "Here’s What the Street is Saying About Amgen Inc. (AMGN)",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Amgen Inc. (NASDAQ:AMGN) was downgraded to Hold from Buy by Freedom Capital, with the firm adjusting the price target on the stock to $375 from $360. It told investors in a research note that while it […]",
    "url": "https://finnhub.io/api/news?id=8c1c54e940997adf282640100b25c627c25578eb4273f833fc374f58909ed777",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771512860,
      "headline": "Here’s What the Street is Saying About Amgen Inc. (AMGN)",
      "id": 139149091,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Amgen Inc. (NASDAQ:AMGN) was downgraded to Hold from Buy by Freedom Capital, with the firm adjusting the price target on the stock to $375 from $360. It told investors in a research note that while it […]",
      "url": "https://finnhub.io/api/news?id=8c1c54e940997adf282640100b25c627c25578eb4273f833fc374f58909ed777"
    }
  },
  {
    "ts": null,
    "headline": "Possible Bearish Signals With Amgen Insiders Disposing Stock",
    "summary": "In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have...",
    "url": "https://finnhub.io/api/news?id=7d18de934ada59bcbf989a3ac5c336d397ae9bfc0ed873f24ab649592c60f086",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771506007,
      "headline": "Possible Bearish Signals With Amgen Insiders Disposing Stock",
      "id": 139146261,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have...",
      "url": "https://finnhub.io/api/news?id=7d18de934ada59bcbf989a3ac5c336d397ae9bfc0ed873f24ab649592c60f086"
    }
  },
  {
    "ts": null,
    "headline": "P/E Ratio Insights for Amgen",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=3c454a235eb8cb31caa8a02c5c3706cab58ff8cf0cf2ad91d6fe07aee64f5fb0",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771498837,
      "headline": "P/E Ratio Insights for Amgen",
      "id": 139159926,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=2048&height=1536",
      "related": "AMGN",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=3c454a235eb8cb31caa8a02c5c3706cab58ff8cf0cf2ad91d6fe07aee64f5fb0"
    }
  },
  {
    "ts": null,
    "headline": "Wells Fargo Maintains Equal-Weight on Amgen, Raises Price Target to $375",
    "summary": "Wells Fargo  analyst Mohit Bansal   maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $325 to $375.",
    "url": "https://finnhub.io/api/news?id=60b4b4326c45f83dd66a087b0b9af596f3c9216284383e248d12bea1975aa337",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771496202,
      "headline": "Wells Fargo Maintains Equal-Weight on Amgen, Raises Price Target to $375",
      "id": 139147231,
      "image": "",
      "related": "AMGN",
      "source": "Benzinga",
      "summary": "Wells Fargo  analyst Mohit Bansal   maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $325 to $375.",
      "url": "https://finnhub.io/api/news?id=60b4b4326c45f83dd66a087b0b9af596f3c9216284383e248d12bea1975aa337"
    }
  },
  {
    "ts": null,
    "headline": "1 Momentum  Stock to Research Further and 2 We Avoid",
    "summary": "The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.",
    "url": "https://finnhub.io/api/news?id=1f5eac93b97fa056df76e6c15a486c7aecffde17cc452060480f574121152530",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771476189,
      "headline": "1 Momentum  Stock to Research Further and 2 We Avoid",
      "id": 139150488,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.",
      "url": "https://finnhub.io/api/news?id=1f5eac93b97fa056df76e6c15a486c7aecffde17cc452060480f574121152530"
    }
  },
  {
    "ts": null,
    "headline": "End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations",
    "summary": "Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Jefferies lowered its price target on Apogee Therapeutics Inc. (NASDAQ:APGE) to $95 from $98 while keeping its Buy rating on the stock. The analyst also reduced its risk-adjusted peak sales forecast for Apogee’s ’279 […]",
    "url": "https://finnhub.io/api/news?id=ce0714d8ec4d50144f3dab504b036719bc11c07a43f87a7fd30cf15b54fbc064",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771461590,
      "headline": "End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations",
      "id": 139140971,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Jefferies lowered its price target on Apogee Therapeutics Inc. (NASDAQ:APGE) to $95 from $98 while keeping its Buy rating on the stock. The analyst also reduced its risk-adjusted peak sales forecast for Apogee’s ’279 […]",
      "url": "https://finnhub.io/api/news?id=ce0714d8ec4d50144f3dab504b036719bc11c07a43f87a7fd30cf15b54fbc064"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Details Oncology R&D Push, IMDELLTRA Expansion and LUMAKRAS Updates at Citi Summit",
    "summary": "Amgen (NASDAQ:AMGN) executives outlined the company’s oncology research and development priorities and provided updates on several key programs during Citi’s Virtual Oncology Leadership Summit. Jean-Charles Soria, senior vice president of global development in oncology, said Amgen’s framework emphas",
    "url": "https://finnhub.io/api/news?id=1dc8760ebeba7b71a615817cff0e4a037f15eaaea39c872acaa4479eacab3999",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771461500,
      "headline": "Amgen Details Oncology R&D Push, IMDELLTRA Expansion and LUMAKRAS Updates at Citi Summit",
      "id": 139140972,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) executives outlined the company’s oncology research and development priorities and provided updates on several key programs during Citi’s Virtual Oncology Leadership Summit. Jean-Charles Soria, senior vice president of global development in oncology, said Amgen’s framework emphas",
      "url": "https://finnhub.io/api/news?id=1dc8760ebeba7b71a615817cff0e4a037f15eaaea39c872acaa4479eacab3999"
    }
  }
]